Allied Academic Publication is an amalgamation of several esteemed academic and scientific associations known for promoting scientific temperament. Established in the year 1997, Andrew John Publishing Group is a specialized Medical publisher that operates in collaboration with the association and societies. This publishing house has been built on the base of esteemed academic and research institutions including The College of Audiologists and Speech Language Pathologists of Ontario(CASLPO), The Association for Public Safety Communications Officials of Canada (APCO), The Canadian Vascular Access Association (CVAA), The Canadian Society of Internal Medicine (CSIM), The Canadian Hard of Hearing Association (CHHA), Sonography Canada, Canadian Association of Pathologists (CAP-ACP) and The Canadian Association of Neurophysiologic Monitoring (CANM).
Dementia, is one of the biggest global public health challenges facing our generation. Worldwide, at least 44 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 115 million. In 2011, an estimated 747,000 Canadians were living with Alzheimer’s or other dementias by 2031, it is estimated that 1.4 million Canadians will have dementia. In Canada 72% of Alzheimer's sufferers are women and 62% of dementia cases are also women. Much of the increase will be in developing countries like Western Europe and North America.
Already 62% of people with dementia live in developing countries. Today, over 35 million people worldwide currently live with the condition. This number is expected to double by 2030 and more than triple by 2050 to 115 million.
No treatments available to slow or stop the brain damage caused by Alzheimer’s disease, several medications can temporarily help improve the symptoms of dementia for some people. In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost $300 billion per year. Globally, dementia cost $600 billion a year.
None of the pharmacologic treatments (medications) available today for Alzheimer’s disease slows or stops the damage and destruction of neurons that cause Alzheimer’s symptoms and make the disease fatal. The six drugs approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s temporarily improve symptoms by increasing the amount of chemicals called neurotransmitters in the brain.A1 The effectiveness of these drugs varies from person to person.
Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums every year on Pharma, Medicine, Science and Technology
Here we welcome you to the 10th World Congress on Dementia during May 25-26, 2018 in the city of New York, USA.
Dementia 2018 mainly focusing on Alzheimer’s disease, Dementia, Imaging Techniques associated with Biomarkers, Various Animal models, Geriatrics and Cognitive Disorder, Pathophysiology, Care practice and Awareness, Current Trends and Awareness in Dementia and Alzheimer’s Disease.
generally caused due to alterations in the structure of brain. Based on the
recent statistical data more than 5 million Americans are living with
dementia and the number is expected to rise up to 16 million by 2050. It’s very
pathetic that for every 66 seconds someone in America are developing
Dementia and related diseases and 1 in 3 die daily with the
Alzheimer's or Dementia. Since 2000, death records of the heart respective diseases were decreased by 14% and drastically the deaths of Dementia related diseases increased to 89%
Why to Attend?
Conduct demonstrations, workshops, and symposiums, distribute information, meet with potential national & international delegates, professors and explore with a new product line, and receive recognition at this 2-day event. World-renowned speakers, the most recent researches, innovations, and the Novel updates in Dementia field are hallmarks of this congress.
Directors, Neurologist, Neurosurgeons, Psychiatrist, Surgeon, Head of department, Industries, Business delegates, Clinicians, Community Members, Professors and Students from Academia in the research of Dementia and related disorders.
Dementia is a term which generally refers to loss of memory and some other mental abilities (reasoning, ability to think etc…) which affects the person’s day to day life. Alzheimer’s disease is the most common type of disease which covers 50-70% cases. The common symptoms of dementia include emotional problems, problem in finding words, lack of motivation etc. The severity of dementia increases with the person’s age. The other common types of diseases which include dementia are vascular dementia, levy body dementia, and front temporal dementia.
Session on Risk factors of
The Dementia is associated with several risk factors in which geriatrics come’s under the first source. The risk factors include both modifiable and unmodifiable symptoms which shares equally according to the patient’s environmental conditions. The modifiable risk factors include smoking, consumption of alcohol, low level education, high blood pressure, diabetes, obesity, and lack of physical activity, whereas the un modifiable factors include hereditary risks, gender, familial and sporadic Alzheimer’s.
Session on Assessment and diagnosis
Alzheimer’s disease is the most common type of dementia which estimates about 26 million people worldwide. It is a serious brain disorder which impacts daily work life of the person. Till date there is no accurate test to show whether the person has dementia and other related diseases. Due to the lack of finding out the cause for the disease, even physicians are not able to detect the accurate disease. Symptoms of the Alzheimer’s disease grow slowly and spread widely over time and thus cause the brain impairment. There is no availability of single test for detecting dementia; instead there are several medical evaluations such as mental status testing, neurological testing, blood test and medical imaging.
Session on Imaging and biomarkers in dementia
A biomarker is an indicator of naturally occurring gene or molecule which is characterized by a particular pathological or physiological process which responses to the therapeutic intervention. In dementia biomarkers are generally used to predict the pre symptomatic pathological changes and also to focus on three commonest neurodegenerative dementias like Alzheimer’s dementia, Front temporal dementia and levy body dementia. The main focus of neuroimaging biomarker is to develop the novel treatment in Alzheimer’s disease, considering Magnetic Resonance Imaging (MRI) as biomarker in imaging process.
Session on Pathophysiology of dementia
Dementia is a symptom associated with specific structural brain diseases and system degenerations. Alzheimer’s disease, which is the most common among all the diseases under dementia, causes cortical-subcortical degeneration of cholinergic neurons and large pyramidal cells in the cerebral cortex. The disease gradually spreads all over the cortex region and deteriorates the function of brain cells. Pathologically the abnormalities are more diffuse and spread in to the sensorimotor cortical too.
Session on Amyloid protein dementia
Amyloids are combinations of proteins which are folded into a shape in order to form several copies of that protein to stick together forming fibrils. Alzheimer’s is referred as a disease due to the misfolding of the protein’s which is generally acknowledged with the term proteopathy. It is caused by plaque accumulation of abnormally folded Amyloid-beta protein and Tau protein in brain which forms amyloid plaques and neurofibrillary tangles.
Session on Neuropharmacology
Neuropharmacology is the study of medicine which has an effect on cellular operation within the system, and thus influences the behavior through neural mechanisms. There are two main branches of neuropharmacology: Behavioral and Molecular.
It focuses on the study of medicine which have an effect on human behavior (Neuro psychopharmacology), along with the study of drug dependence and addiction which affects the human brain.
It involves the study of neurons and their organic compound interactions, with the goal of developing medicine that have useful effects on neurological operations which are closely connected with the interactions of neurotransmitters, neuropeptides, neurohormones etc. Through these interactions researchers are developing medicine to treat various neurologic disorders like Alzheimer’s, psychological disorders, addictions and lots of others.
Session on Cognitive
CST is a compact treatment for the people with mild to moderate dementia. Based on extensive research evidences, management of dementia recommends the use of group cognitive stimulation for people with mild and moderate dementia irrespective of drug treatments. The treatment can be administered by anyone such as care workers, psychologists, occupational therapists, nurses etc. Places like residencies, hospitals and day centers are appropriate for undergoing the therapy.
Session on Therapeutic targets:
Alzheimer’s is an escalating neurodegenerative disease which is designated histopathologically by the presence of plaques made up of Abeta-amyloids and tangles composed of hyperphosphorylated Tau. Till date there is no proper treatment which can reverse the disease and all the current therapeutics is directed to cope with the symptoms of the disease. Research work is carrying out in order to ascertain the process of neurofibrillary degeneration associated with the presence of hyperphosphorylated Tau.
Session on Current trends in
Recent research work indicates the decline in the dementia and related diseases from the past 25 years. These drastic changes are expected due to the increased education levels and awareness on cardiovascular related diseases. Although the findings prove that the risk of dementia at the present age may be slightly decreasing, one should be aware of the population shift older ages. Even though the researches are promising, the social risk of Alzheimer’s and other dementias continue to grow. By 2050, 68% of the people from low and middle income countries are expecting to be affected.
Session on Dementia care
In Dementia, most of the conflicts were found in-between the depression and better level of awareness associated. Dysthymia, however not relate to major depression, it comes under the higher levels of awareness. The patients with less awareness generally suffer with apathy and psychosis. Those with less awareness should be able to share common platform on neuropathological substrates. The person with unawareness generally tends to lack the daily functioning, giving more burdens to the accompanying person and thus leading to deterioration.
Theme: Exploring the challenges concerning excellence in dementia research and care.
On behalf of the conference organizing committee, it is our heartiest welcome you to the “10th world congress on Dementia" during May 25-26, 2018 at New York, USA.”
Importance and Scope
The term dementia doesn’t come under a specific disease; instead it’s an overall term which describes wide range of diseases which are associated with the symptoms like loss of memory, ability to perform regular activities, facing problems in finding words etc. Alzheimer’s, which is one of the common diseases in dementia accounts for 60-70% of cases.
The symptoms are mainly due to the damage of the brain cells and associated neurons. About 46 million people in the world has been estimated to be suffering with dementia by 2015 and it may be increased to 50 million (approx. data) by 2017.whereas in America, about 5.5 million people of all ages are estimated to be suffering with dementia. Among 5.5 millions, It’s been calculated that the people under 65 are about 2, 00,000 suffering with dementia which is referred by the term “younger onset dementia”. By 2020, the people above 65 with dementia are estimated around 5.8 million. In America, Alzheimer’s is accounted as the 6th leading cause of death. The cost of cumulative care for Alzheimer’s patients is estimated to be $236 billion in 2016 and the global cost is estimated to be $605 billion which is equal to the 1% of the world gross product. US Scientists have found that at the age of 65, 1/6th of women have more tendencies to develop Alzheimer’s disease compared to the man with chance of 1 in 11. Dementia rates were high among the African-American women compared to that of the Asia-American women and same way is calculated in the case of men in USA. However based on the environmental risk factors, one can develop the symptoms regardless gender.
Goal of world congress on Dementia 2018 is to furnish an outstanding program for exchange of ideas and interventions by the researchers and scientists who have been inventing the new pathways and novel inter cultural methods for various treatments associated with dementia. We strive to make Dementia 2018 a success with your support and eminent talks about the dementia and perspective care and research works on dementia. We assure you the world class facilities and hospitality entirely during the conference.
The 35.6 million people with dementia across world in 2010 are expected to be double by 2030 to about 65.7 million, and nearly double by 2050 to 115.4 million. It is estimated that as many as 5.1 million people of US are thriving with Alzheimer’s disease and it can be increased with the raising ages. There are currently 390,000 New Yorkers with Alzheimer’s disease or related dementias and it is approximated to be doubled by 2025 nearly an increase of 18% especially to the people aged 65 and above. In New York alone, Medicaid for Alzheimer’s costs around $4.5 billion each year which is the highest cost recorded compared with other cities in USA. It is estimated that nearly 1/3 of seniors who die each year have Alzheimer’s or a related Dementia and it is also estimated that there are about 1 million Alzheimer’s and dementia unpaid caregivers.
The risk of dementia increases with the age and causes mainly due to the brain cell degeneration. Due to the dysfunction of blood vessels after degeneration, blood vessels are unable to receive the oxygen levels properly and hence due to the lack in the supply of oxygen, the brain cells are not able to work properly and thus the risk of memory occurs. Based on the physiological factors and genetic relocations the type of dementia varies from individual to individual but the most common disease is Alzheimer’s which attacks 3/4th of dementia population. The risk of dementia is reaching heights in the developing countries and USA stands in the one of the top 5 countries in developing dementia and related diseases.
Why New York?
The City of New York, frequently called New York City or basically New York, is the most popular city in the United States. With an expected 2015 populace of 8,550,405 dispersed over a land zone of around 302.6 square miles (784 km2), New York City is likewise the most densely populated major city in the United States. Situated at the southern tip of the state of New York, the city is the focal point of the New York metropolitan territory, a standout amongst the most crowded urban agglomerations on the planet. Situated on one of the world's biggest characteristic harbors, New York City comprises of five boroughs or precincts, each of which is a different district of New York State. The five districts – Brooklyn, Queens, Manhattan, The Bronx, and Staten Island – were combined into a solitary city in 1898. Many regions and landmarks of interest in New York City have turned out to be outstanding, and the city got a record of almost 60 million tourists in 2015, facilitating three of the world's ten most went to tourist destinations in 2013. A few sources have positioned New York the most photographed city on the planet.
There a large number of institutes and associations in USA dealing with the researches on Dementia, Alzheimer’s and related neurological disorders. Moreover, there have been many public and patient caregiving programs conducted in USA through several Alzheimer’s/Dementia organizations and thus our organizing committee has finalized the conference venue at New York, USA. It is generally estimated that the average monthly cost for New York memory care is about $5779 per year. A major public health burden facing New York State, Alzheimer’s is projected to impact 700,000 individuals by 2025. Alzheimer’s disease not only affects the individual with the diagnosis, but also the family members who are likely to serve as caregivers. In addition, the disease plays a major economic role by increasing medical costs and affecting employers of caregivers. It is estimated that Alzheimer’s disease costs all health care payers in New York more than $20 billion per year.
USA Market report
It is predicted that the global dementia and movement disorder treatment market will grow more than 4% by 2021 compared with the present CAGR .In addition to that the research analysts identifies the need for disease modifying drugs(DMDS) as one of the primary growth factors for this market. The treatment for dementia is conducted through therapeutic approaches that provide symptomatic relief as the drugs intended for the treatment only treat the symptoms. The existing drugs in the market are unable to attack the underlying cause of the disease and prolong the treatment cost and time duration. This will in turn increase the demand for DMD since it will safely modify the progression of a disease.
For more details, please visit: dementia.alliedacademies.com